SUVEN LIFE SCIENCES
LIMITED
RESULTS FOR Q4 FY
2013
Suven‘s PAT up by
115% for the year ended Mar 2013
14 May’ 2013 : –
SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug
discovery and developmental activities in Central Nervous System disorders, has
announced its audited financial results for the quarter and year ended 31st Mar
2013.
Financial
Highlights
for the 4th Quarter ended Mar’ 2013:
Ø Growth in revenue Rs 747 Mn vs.Rs 629 Mn - Up by 23%
Ø Growth in PAT Rs 86 Mn vs. Rs 71 Mn - Up by 21%
Ø Growth in EBIDTA Rs 141 Mn vs. Rs 135 Mn - Up by 4%
Financial
Highlights
for the year ended
Mar’ 2013:
Ø Growth in revenue Rs 2579 Mn vs.Rs 2042 Mn - Up by 26%
Ø Growth in PAT Rs 308 Mn vs. Rs 144 Mn - Up by 115%
Ø Growth in EBIDTA Rs 542 Mn vs. Rs 250 Mn - Up by 117%
Suven’s major thrust on innovative R&D in Drug
Discovery continues with a spending of Rs 347 Mn (13.4% on revenue) for the
year ended Mar’ 2013.
The Board has recommended a Dividend of Re 0.30 per
share (30% of face value of Rs.1.00 each) for the year 2012-13.
OTHER NEWS ON SUVEN
DURING LAST 2 YEARS :
May 10, 2013 :-Suven Life Sciences secures three
Product Patents for their NCEs in Canada and Eurasia.
April 17, 2013 : -Suven Life Sciences secures 4 Product
Patents for their NCEs in China, Mexico and New Zealand
Feb 12, 2013 : -Suven‘s PAT up by 500 % for the quater
ended Dec 2012
Dec 31, 2012 :-Suven Life Sciences secures 3 Product
Patents for their NCEs in Eurasia & Canada.
Dec 13, 2012 :-Suven Life Sciences secures 5 Product
Patents for their NCEs in China & Korea
Nov 15, 2012:-Suven‘s PAT up by 153% for the quarter
ended 30th September’ 2012
Oct 04, 2012 :-Suven Life Sciences bags Pharmexcil’s
“Platinum Patent Award”
Aug 14, 2012 :-Suven‘s PAT up by 137 % & Turnover
up by 58 % for 1st Quarter ended 30th June 2012
Aug 09, 2012 :-Suven Life Sciences secures 4 Product
Patents for their NCEs in Australia, Canada, Korea and New Zealand.
July 13, 2012 :-Suven to Present at Alzheimer's
Association International Conference (AAIC)
May 22, 2012 :-Suven Life Sciences secures 4 Product
Patents for their NCEs in Japan, Australia, Europe and Eurasia
May 04, 2012 :-Suven‘s PAT up by 137% for 4th Quarter
ended 31st Mar’2012
April 03, 2012 :--Suven Life Sciences secures 4 Product
Patents for their NCEs in China and Korea
February 07, 2012 :-Suven Life Sciences secures 3
Product Patents for their NCEs in Mexico and USA
January 31, 2012 :-Suven‘s revenue up by 57% and EBIDTA
up by 168% for 3rd Quarter ended 31st Dec’2011
December 08, 2011:-Suven Life Sciences secures 4
Product Patents for their NCEs in Australia and Canada
November 14, 2011:-Suven Life Sciences presenting the
Pre-clinical data of their NCEs at Society for Neuroscience (SFN-2011) Annual
Meeting at Washington DC, USA
November 1, 2011:-Suven‘s revenue up by 31% and spends
18% of revenue on R&D;
October4, 2011:-Suven Life Sciences bags Pharmexcil’s
Gold “Patent Award”
September 22, 2011:-Suven Participating at 4th CNS
Partnering & Deal Making Conference in USA
September 5, 2011 :-Suven Life Sciences secures 4
Product Patents for their NCEs in Australia and New Zealand
August 18, 2011:-Suven Life Sciences secures 4 Product
Patents for their NCEs in the key markets in the world
August 13, 2011:-Suven‘s revenue up by 24% and spends
17% of revenue on R&D
July 18, 2011:-Suven presenting at International
Conference on Alzheimer’s disease (ICAD)
June 20, 2011:-Suven Life Sciences secures 2 Product
Patents for their NCEs in the key markets in the world
May 30, 2011:-Suven Spends 20.5% of Revenue on R&D’
PAT up by 48.55% for the year ending
March 2011
May 26, 2011:-Suven Life Sciences secures 4 Product
Patents for their NCEs in several key markets in the world
May 18, 2011:-Suven’s Alzheimer drug candidate SUVN-502
successfully completed all chronic toxicological (tox) studies and demonstrated
very high margin of safety (MOS)
May 09, 2011:-Suven Life Sciences bags “Bio-Excellence
Award at Bangalore India Bio 2011”
April 26, 2011:-Suven Life Sciences secures 7 Product
Patents for their NCEs in several key markets in the world
April 5, 2011:-SUVEN’S UNIT-III RECEIVES US FDA
ACCEPTANCE
Jan 31, 2011:-Suven spends 24% of revenue on R&D; PAT up by 55% for for the 3rd quarter ending
Dec 2010;
Jan 11, 2011:-Suven’s partnering and fund-raising
activity at J.P. Morgan Healthcare Conference 2011
* * *
E N D * * *
No comments:
Post a Comment